[Skip to Content]
[Skip to Content Landing]
Views 150
Citations 0
Comment & Response
May 2016

Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate CancerRelating 33 Years of Patient Clinical Care

Author Affiliations
  • 1International Strategic Cancer Alliance, Jacksonville, Oregon
  • 2Prostate Oncology Specialists, Marina del Rey, California
JAMA Oncol. 2016;2(5):686. doi:10.1001/jamaoncol.2016.0367

To the Editor The article by Hershman et al1 is based on Medicare claims—not actual medical record review and talking with patients. In 1983, I and 3 other American investigators collaborated with Fernand Labrie from Laval University using continuous androgen deprivation (CAD) composed of Eulexin (flutamide) plus the luteinizing hormone–releasing hormone (LHRH) agonist D-Trp6-LHRH (triptorelin pamoate [Trelstar]). In approximately 1989, the US Food and Drug Administration approved the “American counterparts” bicalutamide and leuprolide acetate. In about 1989, a few of my medical oncology colleagues and I began using intermittent androgen deprivation (IAD) but with a far different methodology2,3 than how IAD was administered in SWOG 9346.

First Page Preview View Large
First page PDF preview
First page PDF preview